MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202611081083 A) filed by Noida Institute Of Engineering And Technology Niet on July 01, 2026, for Glycan-Engineered Vesicle System For Dual Delivery Of Doxorubicin And Sorafenib In Liver Cancer.
Inventors include Abhijit Debnath; and Shruti Varshney.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: The present invention discloses a glycan-functionalized bacterial outer membrane vesicle nanosystem designated HA-Man-OMVs@DOX/SOR for synergistic chemo- immunotherapy of hepatocellular carcinoma. The nanosystem comprises outer membrane vesicles isolated from Escherichia coli, surface-engineered with DSPE- PEG2000-hyaluronic acid and DSPE-PEG2000-mannose conjugates through lipid-anchored post-insertion. Hyaluronic acid targets CD44-overexpressing tumor cells and cancer stem cells while mannose targets CD206 on tumor-associated macrophages to reprogram immunosuppressive M2 phenotype to anti-tumor M1 phenotype. Doxorubicin is encapsulated in the aqueous lumen and sorafenib is intercalated in the lipid bilayer achieving dual-compartment co-delivery with synergistic anti-tumor efficacy demonstrated by a combination index of less than one. The nanosystem exhibits pH-responsive drug release, enhanced cellular uptake, significant tumor growth inhibition of 84.6 percent in xenograft models, and favourable biosafety. The invention also discloses the process for preparing the said nanosystem.
Disclaimer: Curated by HT Syndication.
